Liquidia has delivered a very strong share price run in recent years, and with the stock last closing at US$47.87 the key question is whether that price can be explained by the company's earnings power. After such a move, you need to ask if the story in the income statement keeps up with the story in the chart.
-
Over the past 5 years the stock has returned about 885.0%, which puts a lot of weight on whether current earnings can justify this kind of rerating.
-
The recent legal settlement with United Therapeutics, which includes net payments of about US$380.7 million through April 2027, may shape how investors think about Liquidia's future profitability, cash needs and the timing of any earnings contribution from YUTREPIA.
-
Your read on Liquidia is one view; the desks covering it have another. See what analysts think Liquidia's shares could be worth .
The issue now is whether Liquidia's recent share price is supported by its earnings when set against the Fair Ratio benchmark.
If you are weighing whether Liquidia's earnings justify this kind of rerating, it can help to compare that question across 33 high quality undervalued stocks .
Does Liquidia Look Pricey on Earnings?
P/E fits Liquidia because investors are now focused on when earnings from YUTREPIA and the wider portfolio might support the current share price. On this metric, Liquidia trades on a P/E of about 30.9x, compared with a Pharmaceuticals industry average near 15.4x and a peer group closer to 43.1x. That leaves the stock well above the broader sector on earnings, although still shy of the richer valuations seen across its closer peer set.
The Fair Ratio model, which adjusts for factors like the business profile, margins, growth expectations and risk, suggests Liquidia's current P/E sits above the level that would typically line up with those fundamentals, so the shares screen as overvalued on this framework. Because the recent legal settlement around YUTREPIA has sharply reset expectations, the multiple now reflects a lot of optimism about how that agreement will translate into sustained profitability. Explore the numbers behind Liquidia's P/E valuation .
The Liquidia Narrative: What Would Justify Today's Price?
Simply Wall St Narratives for Liquidia pick up where the valuation puzzle leaves off by spelling out which assumptions about growth, profitability and cash generation would need to hold for the stock to trade materially above or below today's level. Each scenario ties Liquidia's potential catalysts and key risks to a specific implied worth, so you can track over time which version of the story is actually unfolding on the Community page.
The bull and bear views on Liquidia are both grounded in the same legal settlement, yet they interpret the trade off between clarity and constraint in very different ways.
Bull case: 11% undervalued
The analyst consensus Narrative on Simply Wall St highlights what supporters focus on in Liquidia's pulmonary hypertension franchise.
"Rapid early adoption of YUTREPIA, with more than 900 prescriptions and over 550 patient starts in about 11 weeks, points to growing physician and patient acceptance of inhaled treprostinil delivered via PRINT technology…"
Discover why this Narrative puts Liquidia at 11% undervalued .
Bear case: 45% overvalued
The bearish analyst Narrative on Simply Wall St emphasizes the cash and label constraints around Liquidia's treprostinil platform.
"The staged net payments of US$380.7 million under the global settlement through 2026 and 2027 introduce a heavy cash call just as Liquidia is funding at least 10 clinical studies…"
Explore why this Narrative puts Liquidia at 45% overvalued .
One more Liquidia question that could matter more than the P/E
For all the focus on Liquidia's valuation, the research checks also flag specific risk signals that could change how you view the whole story, and those details are worth weighing on their own. Take a closer look at 2 warning signs (1 major) before settling on a valuation.
This article is general in nature and was produced with the assistance of AI automation, based on data and analysis from Simply Wall St. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include LQDA .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
